HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Swan, S. K. Articles by Villano, S. A. Search for Related Content PubMed PubMed Citation Articles by Swan, S. K. Articles by Villano, S. A. Social Bookmarking                         What's this?

Pharmacokinetics of Maribavir, a Novel Oral Anticytomegalovirus Agent, in Subjects With Varying Degrees of Renal Impairment

From Hennepin County Medical Center, Minneapolis, Minnesota (Dr Swan); New Orleans Center for Clinical Research, New Orleans, Louisiana (Dr Smith); Orlando Clinical Research Center, Orlando, Florida (Dr Marbury); and ViroPharma Incorporated, Exton, Pennsylvania (Ms Schumacher, Ms Dougherty, Dr Mico, Dr Villano).

The effect of renal function on the pharmacokinetics of maribavir, a novel anticytomegalovirus agent, was evaluated in 12 adults with normal renal function (creatinine clearance [CrCl] >80 mL/min) and 19 adults with renal impairment classified as mild (n = 5), moderate (n = 5), or severe (n = 9), as measured by CrCl 50-80, 30-49, and <30 mL/min, respectively. After a single oral dose of maribavir 400 mg, the pharmacokinetics of maribavir, based on total and unbound plasma concentrations, showed no statistically significant difference between subjects with normal renal function and subjects with mild/moderate or severe renal impairment. Renal impairment was associated with an increase in area under the plasma concentration-time curve (AUC) values for an inactive metabolite of maribavir, VP 44469. Results were consistent with those of previous studies, which showed that very little maribavir was excreted unchanged in urine, whereas about 22% of an oral dose of maribavir is recovered in urine as VP 44469.

Key Words: Maribavir • renal insufficiency • cytomegalovirus • pharmacokinetics

Address for reprints: Address for correspondence: Stephen A. Villano, MD, ViroPharma Incorporated, 397 Eagleview Boulevard, Exton, PA 19341; e-mail: stephen.villano{at}viropharma.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Trofe, L. Pote, E. Wade, E. Blumberg, and R. D Bloom Maribavir: A Novel Antiviral Agent with Activity Against Cytomegalovirus Ann. Pharmacother., October 1, 2008; 42(10): 1447 - 1457. [Abstract] [Full Text] [PDF]

				D. R. Goldwater, C. Dougherty, M. Schumacher, and S. A. Villano Effect of Ketoconazole on the Pharmacokinetics of Maribavir in Healthy Adults Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1794 - 1798. [Abstract] [Full Text] [PDF]

				J. Milbradt, S. Auerochs, and M. Marschall Cytomegaloviral proteins pUL50 and pUL53 are associated with the nuclear lamina and interact with cellular protein kinase C J. Gen. Virol., October 1, 2007; 88(10): 2642 - 2650. [Abstract] [Full Text] [PDF]